ZyVersa Therapeutics, Inc.

Equities

ZVSA

US98987D3008

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-28 pm EDT			5-day change	1st Jan Change
4.254 ^USD	-1.31%		-3.33%	-52.74%

Mar. 25	ZyVersa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 18	ZyVersa Therapeutics, Inc. Announces IRB Approval of Phase 2A Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease	CI

ZyVersa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 21, 2023 at 04:04 pm EDT

ZyVersa Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 78.51 million compared to USD 2 million a year ago. Basic loss per share from continuing operations was USD 1,694.0017 compared to USD 35 a year ago.
For the six months, net loss was USD 82.06 million compared to USD 5.75 million a year ago. Basic loss per share from continuing operations was USD 2,331.0023 compared to USD 87.5001 a year ago.

Latest news about ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
ZyVersa Therapeutics, Inc. Announces IRB Approval of Phase 2A Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease	Mar. 18	CI
HC Wainwright Cuts Price Target on ZyVersa Therapeutics to $12 From $24, Maintains Buy Rating	Mar. 12	MT
ZyVersa Therapeutics, Inc. Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option	Feb. 22	CI
Jobs Data in Focus as Exchange-Traded Funds Advance, Equity Futures Mixed Pre-Bell Thursday	Dec. 07	MT
Top Premarket Decliners	Dec. 07	MT
ZyVersa Prices $5 Million Offering of Common Shares, Warrants	Dec. 07	MT
ZyVersa Therapeutics, Inc. Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100?s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways	Dec. 06	CI
Top Midday Decliners	Nov. 30	MT
ZyVersa Therapeutics Shares Fall Following Announcement of Reverse Stock Split, Increase in Authorized Common Shares	Nov. 30	MT
ZyVersa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
ZyVersa Therapeutics, Inc. Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating that Inflammasome ASC Inhibitor IC 100 Attenuates Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection	Nov. 01	CI
ZyVersa Therapeutics, Inc. Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100's Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease	23-10-25	CI
ZyVersa Therapeutics, Inc. Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues	23-10-04	CI
Zyversa Therapeutics Announces Research Published in the Journal of Clinical Investigation Reinforcing Ic 100?s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues	23-09-22	CI
Zyversa Therapeutics, Inc. Announces Research Published in Frontiers in Immunology Reinforcing Ic 100'S Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases	23-09-12	CI
Wall Street Set to Open Flat Friday as Investors Remain Wary of Potential Interest Rate Hike	23-09-08	MT
Tight Labor Market Weighs on US Equity Futures Pre-Bell Friday	23-09-08	MT
HC Wainwright Starts ZyVersa Therapeutics With Buy Rating, Price Target is $2.50	23-09-08	MT
ZyVersa Therapeutics, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023	23-08-21	CI
ZyVersa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
ZyVersa Therapeutics, Inc. Announces Board Changes	23-08-18	CI
ZyVersa Therapeutics, Inc. Announces European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediatorâ„¢? VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease	23-07-07	CI
ZyVersa Therapeutics, Inc. Announces Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arterial Disease	23-06-20	CI
European Patent Office to Grant Zyversa Therapeutics' Patent Application for Cholesterol Transport Mediator™? Var 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease	23-06-06	CI

Chart ZyVersa Therapeutics, Inc.

Duration

Period

More charts

Company Profile

ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on leveraging advanced technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin or 2HBCD) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS). VAR 200âs active ingredient, 2HBCD, is comprised of seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.

Sector

Biotechnology & Medical Research

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.254 USD

Average target price

70 USD

Spread / Average Target

+1,545.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ZYVERSA THERAPEUTICS, INC.	-52.74%	3.23M
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	115B
REGENERON PHARMACEUTICALS, INC.	+10.80%	105B
BIONTECH SE	-10.84%	22.71B
ARGENX SE	-1.08%	21.83B
GENMAB A/S	-10.42%	18.18B
WUXI APPTEC CO., LTD.	-41.92%	16.52B
BEIGENE, LTD.	-15.11%	16.01B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.14B
SAREPTA THERAPEUTICS, INC.	+17.53%	10.71B

Bio Therapeutic Drugs